Clinical Trial Detail

NCT ID NCT02713529
Title Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Amgen
Indications

non-small cell lung carcinoma

colorectal cancer

pancreatic cancer

Therapies

AMG820 + Pembrolizumab

Age Groups: adult

No variant requirements are available.